BIT.BIO
28.10.2021 10:25:07 CEST | Business Wire | Press release
Today bit.bio welcomes three new members to its board of directors, who bring their respective experience of turning world class science into new industries and company growth. The new directors will provide important guidance as bit.bio scales their proprietary synthetic biology cell programming technology platform, creating products and solutions based on human cells that can transform healthcare from basic research and drug discovery to next generation cell based therapies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005473/en/
Hermann Hauser will be the chair of the board. He brings valuable experience in creating entire new industries and markets through groundbreaking technologies with his experience as co-founder of Arm Ltd. holdings, a world leading UK computer chip company. As an early investor of Solexa (now Illumina), Dr. Hauser laid the foundation for the ongoing synthetic biology revolution with technologies to read the human genome. He is also a key member of the Cambridge science and technology community, as well as a trusted innovation advisor of the UK government. Dr. Hauser is a fellow of the Royal Society, KBE and co-founder of the venture capital firm Amadeus Capital Partners.
Hermann Hauser said:
“I believe bit.bio is well positioned to become one of the defining companies in the synthetic biology field, and I am very excited to take the position of chair of the board. I see world changing potential in their technology and look forward to bringing my experience and expertise to the leadership team. I want to see bit.bio grow into an iconic Cambridge company, creating jobs and new industries, and most importantly, bringing the next generation of medicines to patients.”
Sir Gregory Winter is a Nobel prize winning scientist who invented technologies for making therapeutic monoclonal antibodies, and was directly involved in their industrial development, notably through the start up company Cambridge Antibody Technology Ltd. His inventions underpin many of the therapeutic antibodies in development and on the market, including blockbuster drugs such as Humira, Herceptin, Avastin and Keytruda. More recently, through Bicycle Therapeutics, he has been helping to develop another invention - the use of bicyclic peptides as a platform for novel therapeutics.
Sir Gregory Winter said:
“I think we are still in the foothills when it comes to the use of human cells for therapeutic applications, and I am excited to join bit.bio on their journey to the peaks. With access to potentially unlimited numbers of human cells at defined states of differentiation, we could do so much more for patients - whether researching difficult to treat, complex diseases, screening potential drugs on human cells, or developing precision cell therapies at an affordable cost. And the opti-ox technology seems to offer a realistic path to scale those peaks.”
Alan S. Roemer will bring his entrepreneurial expertise from the biotechnology sector to bit.bio. As a life sciences executive and board director, he will offer meaningful capital markets and operational business building experience to ensure that bit.bio is well-financed and well-positioned to scale. Mr. Roemer has launched three multi-billion dollar biotechnology companies, raised over $1.75 billion in private and public capital, and consummated five IPOs. He was a founding leadership team member of Pharmasset (acquired by Gilead Sciences for $11 billion ) and Roivant Sciences, a company developing innovative medicines through a novel form of industrial organisation in R&D. His experience at Roivant is particularly relevant to bit.bio’s strategy to build its cell coding technology opti-ox into multiple verticals where human cells are applied to research, drug discovery and cell therapies. In addition to serving as a member of the board, Mr. Roemer will chair the audit and compensation committees.
Alan Roemer said:
"bit.bio is at that exciting stage of growth and evolution that I have been through several times before. It fuels my entrepreneurial spirit with the ‘fun factor’ of company expansion and cultural impact. I am excited to help the leadership team ‘see around corners’ using my experience from my other high-growth companies. Most importantly, I want to provide meaningful guidance to finance and scale the business, exploit the full potential of bit.bio’s core technology and have the potential to positively impact patients' lives.”
Mark Kotter, founder and CEO of bit.bio said:
“I’m humbled to be bringing together three world leaders in science, entrepreneurship and industry making for the board of bit.bio. The expertise and experience our new board will bring to the company will give our technology the best chance to transform healthcare for every patient, everywhere.”
- ENDS -
About bit.bio
Accelerated biomedical research, new generations of cures, increased global sustainability. These are in reach when biology transitions to engineering.
At bit.bio, we work relentlessly to achieve this goal. We combine the concepts of coding and biology to provide human cells for research, drug discovery, and a new generation of medicines.
For more information visit bit.bio
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005473/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Media Release: Financial Worries Rise and Match Health Concerns as Cost-of-Living Pressures Mount in 20266.7.2026 10:00:00 CEST | Press release
Globally, people are united in their top personal worries: Financial and health issues rank at the top in 2026, averaging 13 percentage points ahead of other concerns.Financial pressure is prominent across Europe, rising in France, Germany, and U.K., and emerging as a top concern in newly measured markets, Spain and Switzerland.Allianz published these results in “The Allianz 3am Report 2026,” which surveyed 10,000 people across 10 countries worldwide about what keeps them awake at night.Addressing financial concerns requires accessible, targeted financial and risk education. To support this, Allianz has launched the “Allianz School For Life” learning platform. Households around the world are feeling the strain of the rising cost of living, with financial pressure increasingly shaping everyday choices and long-term confidence. Finances and health are now tied as the top global worries, at 48% each, followed by concerns about the future at 35%, according to consumer surveys in 10 countri
HAZAMA ANDO Becomes an Official Partner in Helical Fusion’s Commercial Fusion Initiative and Signs MoU Toward Construction of the Fusion Pilot Plant6.7.2026 08:40:00 CEST | Press release
A long-established Japanese general contractor will contribute construction expertise to advance Fusion Pilot Plant development toward commercially viable fusion power. Helical Fusion Co., Ltd. (“Helical Fusion”), a Japan-based fusion energy startup developing fusion power plants, and HAZAMA ANDO CORPORATION (“HAZAMA ANDO”), a long-established Japanese general contractor, today announced that HAZAMA ANDO has become an Official Partner in the Helix Program, Helical Fusion’s commercial fusion initiative. The two companies have also signed a memorandum of understanding (“MoU”) to collaborate toward the construction of Helix KANATA, Helical Fusion’s Fusion Pilot Plant targeted for the 2030s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706176052/en/ (L-R) Kazuhiko Kuniya (Representative Director and President, HAZAMA ANDO CORPORATION) and Takaya Taguchi (Co-Founder and CEO, Helical Fusion Co., Ltd.) at a press conference in
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis6.7.2026 07:15:00 CEST | Press release
Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exitThe proposed acquisition combines the oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumor typesMyricx Bio's first-in-class NMTi payload platform is designed to improve the therapeutic index of ADCs, offering the potential for more effective and better-tolerated treatment options for cancer patientsThe transaction valued at up to $1.5 billion including $1.1 billion cash upfront Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years. Myricx Bio is a UK-headquartered transatlantic biotech company focused on the discove
Global New Material International Wins Technology Innovation Best Practice Award at Sino-European ESG Conference6.7.2026 05:59:00 CEST | Press release
Global New Material International Holdings Ltd. has received the Technology Innovation Best Practice Award at the Third Sino-European Corporate ESG Best Practice Conference recently in Mainz, Germany, in recognition of its efforts to advance sustainable development through material innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260705533555/en/ Thorsten Giehler (L), Director of the Economic, Social Development and Employment Division of The German Society for International Cooperation (GIZ), delivered the award to Zhou Fangchao, Executive Director and Vice President of Global New Material International. The annual conference, initiated by the Chinese Consulate General in Frankfurt and jointly organized with Chinese and European partners, recognizes corporate best practices in environmental, social and governance (ESG) performance. This year's event brought together government officials, business leaders and exper
Access Advance Welcomes Samsung and Sharp to the VVC Advance Patent Pool6.7.2026 02:00:00 CEST | Press release
Access Advance LLC today announced significant additions to the VVC Advance Patent Pool, including Samsung Electronics and Sharp Corporation joining as both Licensors and Licensees. The additions strengthen Access Advance's position in VVC licensing, bringing two of the world's largest video codec patent holders into the program on both sides of the license. "The growth we are seeing in VVC Advance reflects the broad range of industries and companies that are moving toward VVC as the next standard for video delivery," said Peter Moller, CEO of Access Advance. "Samsung and Sharp joining as both Licensors and Licensees is significant, but so is the participation of leading smartphone brands and the range of consumer electronics and technology companies now executing licenses. We are building a program that reflects where the video market is actually heading." The following companies have joined the VVC Advance Patent Pool as Licensees since the beginning of 2026: American Future Technolo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom